Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer

被引:0
作者
Lisha Wang
Fei Ren
Qifeng Wang
Lee Ann Baldridge
M. Francesca Monn
Kurt W. Fisher
Weiqi Sheng
Xiaoyan Zhou
Xiang Du
Liang Cheng
机构
[1] Fudan University Shanghai Cancer Center,Department of Pathology
[2] Fudan University,Department of Oncology, Shanghai Medical College
[3] University of Michigan,Michigan Center for Translational Pathology
[4] Indiana University School of Medicine,Department of Pathology and Laboratory Medicine
来源
Molecular Diagnosis & Therapy | 2016年 / 20卷
关键词
Colorectal Cancer Patient; Immune Checkpoint; Multiple Cancer Type; Patient Clinical Outcome; Immunosuppressive Tumor Microenvironment;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:175 / 181
页数:6
相关论文
共 200 条
[1]  
Cunningham D(2010)Colorectal cancer Lancet 375 1030-1047
[2]  
Atkin W(2014)Colorectal cancer Lancet 383 1490-1502
[3]  
Lenz HJ(2015)Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus Future Oncol 11 2711-2719
[4]  
Lynch HT(2012)Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma Clin Cancer Res 18 850-857
[5]  
Minsky B(2010)Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer Gut 59 926-933
[6]  
Nordlinger B(2008)PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677-704
[7]  
Brenner H(2015)The journey from discoveries in fundamental immunology to cancer immunotherapy Cancer Cell 27 439-449
[8]  
Kloor M(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454
[9]  
Pox CP(2012)Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2455-2465
[10]  
Fisher KW(2010)Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 3167-3175